What is ImmunityBio?
ImmunityBio operates as a vertically-integrated biotechnology enterprise dedicated to the advancement of next-generation therapies and vaccines. By leveraging a sophisticated suite of immunotherapy and cell therapy platforms, the company aims to modulate the human immune system to effectively combat cancer and infectious diseases. A cornerstone of its portfolio is ANKTIVA, an FDA-approved immunotherapy for non-muscle invasive bladder cancer, which represents a significant shift toward more accessible and less toxic treatment modalities compared to traditional high-dose chemotherapy. The company's strategic focus remains on creating durable, safe, and highly effective immune responses through its innovative scientific pipeline.
How much funding has ImmunityBio raised?
ImmunityBio has raised a total of $1.2B across 7 funding rounds:
Other Financing Round
$470M
Debt
$157M
Private Equity
$50M
Share Placement
$40M
Other Financing Round
$320M
Share Placement
$75M
Other Financing Round
$75M
Other Financing Round (2021): $470M with participation from Dr. Patrick Soon-Shiong and NantCapital
Debt (2022): $157M, investors not publicly disclosed
Private Equity (2023): $50M, investors not publicly disclosed
Share Placement (2023): $40M, investors not publicly disclosed
Other Financing Round (2024): $320M backed by Oberland Capital
Share Placement (2025): $75M, investors not publicly disclosed
Other Financing Round (2026): $75M led by Oberland Capital
Key Investors in ImmunityBio
Oberland Capital
Oberland Capital is a private investment firm focused on funding innovation in the global healthcare industry, managing approximately $3 billion in assets. The firm specializes in flexible investment structures tailored to meet the specific needs of its partners, offering a range of financing solutions including monetization of royalty streams and project-based financing.
Dr. Patrick Soon-Shiong
A prominent figure in the biotechnology sector, Dr. Soon-Shiong provides strategic backing and leadership to companies focused on transformative medical research and immunotherapy.
NantCapital
NantCapital is an investment firm that supports high-growth companies in the life sciences and technology sectors, focusing on long-term value creation through strategic capital deployment.
What's next for ImmunityBio?
With the recent capital injection, ImmunityBio is positioned to accelerate its clinical trial milestones and scale the commercial distribution of its breakthrough therapies. The company's roadmap involves deepening its research into cancer vaccines and expanding the reach of its cell therapy platforms. By reducing reliance on standard chemotherapy, ImmunityBio is effectively carving out a leadership position in the precision medicine sector. Future strategic initiatives will likely prioritize the optimization of manufacturing processes and the pursuit of additional regulatory approvals, ensuring that its therapeutic candidates reach a broader patient demographic while maintaining high standards of clinical efficacy.
See full ImmunityBio company page
